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This study reports findings from a 56-year-old patient, who had received bilateral intravitreal injection of putative adipose tissue-
derived stem cells at a private clinic in India with the promise of treatment of NAION. During an observation period of 8,
respectively, 18 months, the intravitreally injected cells remained silent in the vitreous bodies without either therapeutic effects
or complications. The cells cleared with vitrectomy without evidence of integration in the optic nerve or retina. Contrary to
recent reports on patients receiving intravitreal injections of similar putative stem cells with the aim of treating AMD, our
patient suffered no devastating ocular consequences. Summary. Contrary to recent reports, this case demonstrated no
devastating consequences of intravitreal injection of adipose tissue-derived stem cells during an observation period of up to 18
months. After vitrectomy, the cells cleared without evidence of either harm or integration.
1. Introduction
Stem cells have emerged as a promising therapeutic modality
for multiple diseases [1–3]. Besides bone marrow and limbal
transplantation, much needs to be learned before stem cell
therapy can reach clinical practice. Despite this lack of
knowledge about safety and efficacy, private clinics in several
countries offer stem cell therapy promising treatment of mul-
tiple diseases.
Recent reports have described four cases of putative
adipose tissue-derived “stem cells” injected intravitreally
in patients (aged 72 to 88 years) with age-related macular
degeneration in two different private clinics [4, 5]. While
devastating consequences of the procedures, including
retinal hemorrhage and detachment with proliferative
vitreoretinopathy (PVR) in almost all injected eyes, were
described in detail, the actual fate of the injected stem cells
was not described.
2. Case
A 56-year-old male with vision loss from sequential nonar-
teritic anterior ischemic optic neuropathy (NAION) with a
complete visual field defect and a visual acuity of 1/50 Snellen
in each eye (Figure 1(a)) was seen acutely due to a further,
painless decrease in visual acuity in both eyes. A visual acuity
of light perception was noted. On examination, whitish,
dense vitreal opacities partly obscuring views of deeply atro-
phic optic nerves and otherwise unremarkable retinas were
seen. The conjunctivae were white and no anterior uveitis
was seen.
The patient revealed that two months earlier he received
intravitreal injections in both eyes of putative stem cells pre-
pared from his abdominal subcutaneous adipose tissue. The
full procedure from harvesting of adipose tissue to intravit-
real injection had a total duration of about two hours and
was carried out at a private clinic in New Delhi, India. Fur-
ther details about the procedure were not known.
The patient was observed and demonstrated a stable con-
dition for several months (Figure 1(a)). Eight months after
stem cell injection, we performed vitrectomy in the left eye
and—after a further 10 months—also in the right eye. The
dense opacities were purely localized to the vitreous bodies
and cleared completely with vitrectomy (Figure 1(b) and
video, supplementary material (available here)). The hyaloids
were very adherent to the retinae which probably was the
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cause of the intraoperative complications: in the left eye a
localized retinal detachment was induced and in the right a
retinal tear was induced, both were treated accordingly. Spec-
imens from both eyes were examined microscopically and
included few vimentin-positive cells compatible with cells
of mesenchymal origin. We did not identify cells differenti-
ated into a retinal or neuronal phenotype. Following the
immediate postoperative period, no intraocular reaction
was observed in either eye. Visual acuity remained poor.
Epiretinal remnants from the adherent hyaloid were noted
in the right eye, and these remained unchanged for several
months (Figure 1(c)).
3. Discussion
This case demonstrates that cell suspensions of putative stem
cells may be injected intravitreally without severe adverse
effects. Whether this was due to entrapment in the vitreous
body or simply lack of function of putative stem cell popula-
tion is not known. The posterior hyaloid was very adherent in
both eyes, which may be an effect from or a response to the
intravitreally placed cell population. We did, however, not
note any signs of cellular integration in the retina or the optic
nerve and certainly no therapeutic effect was noted.
The cell suspensions remained intravitreally for 8-18
months. Besides unchanged vitreal clouding, no serious
adverse effects were noted in the observation period. In
agreement with the immune privilege of the eye including
the vitreous, this demonstrates that heterogeneously trans-
planted cells can remain silent without inducing an inflamma-
tory response in the vitreous. This is unlike previous reports
where intravitreal injections of similar adipose tissue-derived
cell populations resulted in early and serious complications
in all treated eyes. This included high intraocular pressure,
anterior uveitis, lens subluxation, vitreal and intraretinal
hemorrhage, and retinal detachment with aggressive PVR
[4, 5]. This difference may relate to different methods of
harvesting and isolating adipose tissue-derived stem cells
resulting in debris or toxicity inducing these reactions rather
than a reaction to the cell isolate per se. We speculate that
another explanation for the observed clinical difference could
be the absence of posterior vitreous detachment. In the pres-
ent case, cell suspensions were probably injected into the per-
sistent vitreous bodies. In the previous cases, all patients were
older than 70 years with end-stage AMD, and the cell suspen-
sions were probably injected in close contact with the retina
due to posterior vitreous detachment.
The stem cell technique holds great promise for treat-
ment and cure of a wide range of diseases; however, more
research is needed. Currently, some private clinics, with a
promise of cure, are exploiting patients with untreatable dis-
eases. This case demonstrates that patients should be dis-
couraged from such unethical and costly treatments.
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